Effectiveness and safety of de-escalation of methotrexate and/or baricitinib after achieving remission or low disease activity in patients with rheumatoid arthritis RA-BE-LEAVE study (RA-BE-LEAVE study)

Start Date13 Feb 2023

Sponsor / Collaborator-

NCT02946203

/ CompletedPhase 4IIT

Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography

In this research study, two different oral contrast materials that can be used for CT or MR enterography will be studied. This study is designed to compare which oral contrast material (VoLumen or Breeza) is preferred by pediatric patients and which provides higher quality exams.

Start Date01 Nov 2016

Sponsor / Collaborator

Children's Hospital & Medical Center

100 Clinical Results associated with Barium Sulfate

100 Translational Medicine associated with Barium Sulfate

100 Patents (Medical) associated with Barium Sulfate

4,111

Literatures (Medical) associated with Barium Sulfate

01 Jun 2026·FOOD HYDROCOLLOIDS

Effect of barium sulfate, thickener type, and saline solution on the rheological properties of liquids used for instrumental swallowing assessment

Article

Author: Rogus-Pulia, Nicole ; Freire, Dieyckson O ; Peña-Chávez, Rodolfo ; Hartel, Richard W ; Ciucci, Michelle ; Nicosia, Mark ; Steele, Catriona M ; McCulloch, Timothy

Thickened liquids are often recommended for people with swallowing dysfunction (dysphagia). During instrumental swallowing assessment, barium sulfate and saline are added to these liquids for radiopacity and signal conductivity. Although assumed to mimic everyday nutritional beverages, the addition of such agents may change their rheology, challenging this assumption. This study aimed to determine the effect of barium sulfate, thickener type, and saline on the rheological properties of liquids used for instrumental swallowing assessment. Liquids were prepared with combinations of barium sulfate, thickeners, and saline. Shear viscosity, extensional viscosity, yield stress, and surface tension were measured. Optical light microscopy was used to analyze the internal structure of all liquids. A 2³ factorial design was developed, and statistical analyses included multivariate linear regression, three-way ANOVA, and Pearson's correlation coefficients. Shear viscosity at 50 s^-1 increased when barium and starch thickener were present. Extensional viscosity increased when the combination of barium, starch, and saline was present. All added ingredients affected the breakup time. Yield stress and surface tension both decreased when the combination of barium and saline was present. Shear viscosity correlated negatively with extensional viscosity and surface tension, while extensional viscosity and breakup time were positively correlated with yield stress. In conclusion, barium sulfate and thickener type modified all rheological parameters. While barium is mandatory for videofluoroscopy, the flow properties of thickened liquids may be affected, thereby influencing the validity of findings obtained during videofluoroscopy. Future work will examine how changes in these rheological parameters influence swallowing function in adults.

07 Apr 2026·Microbiology Spectrum

Different combinations of lignocellulolytic enzymes and lactic acid bacteria affect the quality and aerobic stability of rain-soaked Sudan grass silage by regulating the silage microbial community

Article

Author: Long, YiXi ; Xie, Yixiao ; Li, Mengxin ; Yu, Qiang ; Sun, Hong ; Rong, Yuanjiang ; Zheng, Yulong ; Yang, Fuyu ; Su, Ya ; Hao, Jun

ABSTRACT:

This study evaluated the effects of ferulic acid esterase (FAE)-producing Lactiplantibacillus plantarum (LP; 1 × 10⁶ cfu·g⁻¹ FM), applied alone or with cellulase and xylanase (LCX; each enzyme 25 U·g⁻¹ FM) or cellulase and laccase (LCL; each enzyme 25 U·g⁻¹ FM), on the ensiling of rain-affected Sudan grass. After wilting to 75% moisture, the forage was vacuum-sealed in polyethylene bags and ensiled for 60 days, followed by 7 days of aerobic exposure. The LCX treatment significantly enhanced fermentation quality, yielding the lowest pH (3.83, P < 0.05), highest lactic acid (LA, 54.03 g·kg −1 DM, P < 0.05), and water-soluble carbohydrate (WSC, 21.45 g·kg −1 DM, P < 0.05) contents, and promoting the degradation of cellulose and hemicellulose after 60 days of ensiling. However, it resulted in the poorest aerobic stability. In contrast, the LCL treatment effectively reduced lignin and butyric acid (BA, 1.34 g·kg −1 DM, after 7 days of aerobic exposure, P < 0.05) contents, decreased fungal diversity, and increased acetic acid (AA, 4.82 g·kg −1 DM, P < 0.05), crude protein contents, and the relative abundance of Lentilactobacillus ( P < 0.05), leading to superior aerobic stability exceeding 168 h, with stable nutritional and fermentation characteristics maintained after aerobic exposure. Both control and LP-only silages showed poor fermentation quality, with high pH (>5.16), substantial butyric acid production, nutrient loss, and proliferation of undesirable microbes such as Enterobacter and Clostridium . In conclusion, ensiling rain-soaked Sudan grass requires synergistic additives. While LCX enhances fermentation quality, LCL is recommended for effectively improving both fermentation quality and aerobic stability, offering a practical strategy for rainy regions.

IMPORTANCE:

Ensiling rain-soaked forages is a major challenge for livestock production in rainy regions, as it often leads to poor fermentation, nutrient loss, and rapid spoilage. This study demonstrates that tailored microbial-enzyme combinations can effectively overcome these issues. While adding specific enzymes with bacteria significantly improves the silage's nutritional value, it can make the silage prone to spoilage upon air exposure. Crucially, we found that incorporating a lignin-degrading enzyme (laccase) instead creates a more robust silage that resists spoilage for a remarkably longer time. This provides a practical and sustainable strategy for farmers to produce high-quality, stable silage from Sudan grass even when harvested under wet conditions, ensuring a reliable feed supply and supporting sustainable livestock farming in rainy climates like Southwest China.

01 Feb 2026·Ear, nose, & throat journal

Diagnosis and Open Surgical Management of Laimer’s Diverticulum: Case Series and Review of the Literature

Review

Author: Li, Wan-Xin ; Dong, Yan-Bo ; Lu, Cheng ; Guo, Ting-Ting ; Liu, Yu-He

Objectives: Laimer’s diverticulum (LD) is a very rare clinical entity originating between the cricopharyngeus muscle (CPM) and circular muscular fibers of the esophagus. Its diagnosis and management remain to be elucidated. This article summarizes our experience in its diagnosis and open surgical management. Methods: A retrospective review of LD cases treated at our tertiary medical institution was conducted between July 2018 and May 2023. The clinical and demographic data were retrieved from case notes. Results: Three cases were included in this review. There were 2 male patients and 1 female patient. The average and median ages were 47.3 and 54 years, respectively. Presenting symptoms included hoarseness, pharyngeal foreign body sensation, and neck mass. All 3 diverticula were on the left side, with the first 2 cases discovered accidentally on gastric endoscopic or cervical MRI examinations. After evaluating esophageal swallowing with barium sulfate or urografin contrast media, all the patients consented to undergo an open surgical procedure. During surgical exploration, the diverticula were found to be on the posterior part of the cervical esophagus, below CPM, and away from the recurrent laryngeal nerve, and only then, could the diagnosis of LD be established. Then, diverticulectomy and manual suturing of the esophagus was performed. Recovery of all 3 patients was uneventful. Nasogastric tube feeding lasted 7 to 12 days until esophageal examinations demonstrated no leak, and then, oral liquid feeding resumed. The median duration of follow-up was 50 months. No recurrence of symptoms or diverticulum was observed, and the swallowing function of all 3 patients was excellent. Conclusions: An open surgical approach is not only important for the diagnosis of LD, but can also be utilized as a safe and effective treatment.

News (Medical) associated with Barium Sulfate

30 Sep 2025

·www.einpresswire.com

April - June 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Acetaminophen-containing products Anaphylactic reaction FDA is evaluating the need for regulatory action. Aptryxol (desvenlafaxine) DaTscan (ioflupane I 123 injection) Desvenlafaxine extended-release tablets Effexor XR (venlafaxine extended-release) capsules Pristiq (desvenlafaxine) extended-release tablets Venlafaxine (venlafaxine hydrochloride) extended-release tablets False positive radioisotope investigation test result potentially secondary to a drug interaction with venlafaxine FDA is evaluating the need for regulatory action. Barium sulfate-containing products Entero Vu 24% (barium sulfate) oral suspension E-Z-Disk (barium sulfate) tablets Liquid E-Z-Paque (barium sulfate) oral suspension Readi-Cat 2 (barium sulfate) oral suspension Readi-Cat 2 Smoothie (barium sulfate) oral suspension Taglitol V (barium sulfate) oral suspension Varibar Honey (barium sulfate) oral suspension Varibar Nectar (barium sulfate) oral suspension Varibar Pudding (barium sulfate) oral paste Varibar Thin Honey (barium sulfate) oral suspension Varibar Thin Liquid (barium sulfate) oral suspension Anaphylactic reaction FDA is evaluating the need for regulatory action. Blincyto (blinatumomab) for injection Columvi (glofitamab-gxbm) injection Elrexfio (elranatamab-bcmm) injection Epkinly (epcoritamab-bysp) injection Imdelltra (tarlatamab-dlle) for injection Kimmtrak (tebentafusp-tebn) injection Lunsumio (mosunetuzumab-axgb) injection Talvey (talquetamab-tgvs) injection Tecvayli (teclistamab-cqyv) injection Progressive multifocal leukoencephalopathy FDA is evaluating the need for regulatory action. BRAF kinase inhibitors Braftovi (encorafenib) capsules Ojemda (tovorafenib) for oral suspension; tablets Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablets Gingival hypertrophy FDA is evaluating the need for regulatory action. Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Acute hepatic failure The "Warnings and Precautions" section of the labeling was updated in August 2025 to include information about liver injury. Example: Briumvi labeling Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection Central nervous system infection FDA is evaluating the need for regulatory action. Crexont (carbidopa and levodopa) extended-release capsules Dhivy (carbidopa and levodopa) tablets Duopa (carbidopa and levodopa) enteral suspension Rytary (carbidopa and levodopa) extended-release capsules Sinemet (carbidopa and levodopa) tablets Sinemet CR (carbidopa and levodopa) sustained-release tablets Stalevo (carbidopa, levodopa and entacapone) tablets Vyalev (foscarbidopa and foslevodopa) injection Seizure FDA is evaluating the need for regulatory action. Crysvita (burosumab-twza) injection Hypercalcemia The "Dosage and Administration", "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in August 2025 to include information about hypercalcemia. Crysvita labeling Dexmedetomidine-containing products Dexmedetomidine injection Precedex (dexmedetomidine hydrochloride) injection Igalmi (dexmedetomidine) sublingual film Diabetes insipidus FDA is evaluating the need for regulatory action. Dupixent (dupilumab) injection Ocular infections, irritations, and inflammation FDA is evaluating the need for regulatory action. Eprontia (topiramate) oral solution Qudexy XR (topiramate) extended-release capsules Qsymia (phentermine and topiramate) extended-release capsules Topamax (topiramate) tablets Topamax Sprinkle (topiramate) capsules Trokendi XR (topiramate) extended-release capsules Hypersensitivity FDA is evaluating the need for regulatory action. Gavreto (pralsetinib) capsules Chylothorax FDA is evaluating the need for regulatory action. Glucagon-like peptide-1 (GLP-1) receptor agonists Adlyxin (lixisenatide) injection Bydureon (exenatide) for extended-release injectable suspension Bydureon BCise (exenatide extended-release) injectable suspension Byetta (exenatide) injection Mounjaro (tirzepatide) injection Ozempic (semaglutide) injection Rybelsus (semaglutide) tablets Saxenda (liraglutide) injection Soliqua 100/33 (insulin glargine and lixisenatide) injection Trulicity (dulaglutide) injection Victoza (liraglutide) injection Wegovy (semaglutide) injection Xultophy 100/3.6 (insulin degludec and liraglutide) injection Zepbound (tirzepatide) injection Intestinal obstruction and fecal impaction FDA is evaluating the need for regulatory action. Imbruvica (ibrutinib) capsules; tablets; oral suspension Nail and nail bed conditions (excluding infections and infestations) FDA is evaluating the need for regulatory action. MEK inhibitors Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Koselugo (selumetinib) capsules Gingival hypertrophy FDA is evaluating the need for regulatory action. Neffy (epinephrine nasal spray) Product storage error FDA is evaluating the need for regulatory action. Nurtec ODT (rimegepant) orally disintegrating tablets Zavzpret (zavegepant) nasal spray Anaphylactic reaction The "Contraindications" and "Warnings and Precautions" sections of the labeling were updated in August 2025 to include information about hypersensitivity reactions, including anaphylaxis. Example: Nurtec ODT labeling Rozlytrek (entrectinib) capsules; oral pellets Brugada syndrome FDA is evaluating the need for regulatory action. Sodium-glucose cotransporter-2 (SGLT2) inhibitors Fournier's gangrene FDA is evaluating the need for regulatory action. Teriparatide injection (a particular generic product) Device malfunction FDA is evaluating the need for regulatory action. Vizamyl (flutemetamol F18 injection) Anaphylactic reaction The "Warnings and Precautions" section of the labeling was updated in June 2025 to include information about anaphylaxis and other serious hypersensitivity reactions. Vizamyl labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalBiosimilar

16 Dec 2024

·www.prnewswire.com

Bracco Diagnostics Inc. Introduces Innovative "Mini" Packaging for VARIBAR® (barium sulfate), Catering to Diverse Customer Needs

New packaging solution enhances sustainability, workflow efficiency, and patient throughput PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Bracco Diagnostics Inc. (BDI), a U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, and a pioneer in healthcare innovation, proudly unveils its latest breakthrough in barium solutions: the "Mini" Packaging for VARIBAR® (barium sulfate) oral suspension. Designed to meet the diverse needs of healthcare providers, this packaging option offers smaller volumes of VARIBAR products, the gold standard in Modified Barium Swallow Studies (MBSS). Mini packaging will be available for VARIBAR® NECTAR (barium sulfate) oral suspension, VARIBAR® THIN HONEY (barium sulfate) oral suspension, VARIBAR® HONEY (barium sulfate) oral suspension, and VARIBAR® PUDDING (barium sulfate) oral paste. Time-tested, trusted, and FDA-approved, the legacy of standardized viscosities of the VARIBAR product line helps eliminate the unpredictability of varied barium preparations.1-4 The "Mini" Packaging is a significant milestone as it enhances procedural efficiency and patient care. "The VARIBAR line of products, with standardized viscosities, consistently addresses the most important needs in Modified Barium Swallow Studies," said Cosimo De Pinto, Senior Vice President of Sales and Marketing at BDI. "Now, with this new additional packaging solution, VARIBAR products are available to clinicians in sustainable, smaller volume options." The key features of this innovative packaging include: Tailored Solutions: Healthcare providers can now access VARIBAR products in smaller quantities, optimizing resource utilization and reducing waste. Sustainability: BDI prioritizes using recyclable and biodegradable materials in manufacturing the "Mini" packaging, as it promotes a circular economy thereby reducing reliance on single-use plastics. Streamlined Workflow: The "Mini" Packaging facilitates smoother administration of VARIBAR contrast, enhancing workflow efficiency and patient throughput. "This new packaging minimizes product waste, thereby reducing the environmental footprint of healthcare procedures," said Amy King, Director of Sustainability at BDI. "Compact packaging optimizes storage space and transportation efficiency, further reducing consumption and emissions." By offering VARIBAR products in a more versatile and accessible format, BDI continues to invest in the future of abdominal radiology. The "Mini" Packaging for VARIBAR products is now available for order from all BDI wholesalers and distributors. For more information, please visit . Please see Important Safety Information below. VARIBAR® (barium sulfate) INDICATIONS VARIBAR® THIN HONEY (barium sulfate) oral suspension, VARIBAR® NECTAR (barium sulfate) oral suspension, and VARIBAR® THIN LIQUID (barium sulfate) oral suspension are radiographic contrast agents indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. VARIBAR® HONEY (barium sulfate) oral suspension and VARIBAR® PUDDING (barium sulfate) oral paste are radiographic contrast agents indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients 6 months of age and older. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS These products should not be used in patients with known or suspected perforation of the gastrointestinal (GI) tract; known obstruction of the GI tract; high risk of GI perforation such as those with a recent GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to the pelvis; high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation; known severe hypersensitivity to barium sulfate or any of the excipients of the product used. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Barium sulfate preparations contain a number of excipients, including natural and artificial flavors, and may induce serious hypersensitivity reactions. The manifestations include hypotension, bronchospasm and other respiratory impairments, and dermal reactions including rashes, urticaria, and itching. A history of bronchial asthma, atopy, food allergies, or a previous reaction to a contrast agent may increase the risk for hypersensitivity reactions. Emergency equipment and trained personnel should be immediately available for treatment of a hypersensitivity reaction. Intra-abdominal Barium Leakage The use of VARIBAR PRODUCTS is contraindicated in patients at high risk of perforation of the GI tract. Administration of VARIBAR PRODUCTS may result in leakage of barium from the GI tract in the presence of conditions such as carcinomas, GI fistula, inflammatory bowel disease, gastric or duodenal ulcer, appendicitis, or diverticulitis, and in patients with a severe stenosis at any level of the GI tract, especially if it is distal to the stomach. The barium leakage has been associated with peritonitis and granuloma formation. Delayed Gastrointestinal Transit and Obstruction Orally administered barium sulfate may accumulate proximal to a constricting lesion of the colon, causing obstruction or impaction with development of baroliths (inspissated barium associated with feces) and may lead to abdominal pain, appendicitis, bowel obstruction, or rarely perforation. Patients with the following conditions are at higher risk for developing obstruction or baroliths: severe stenosis at any level of the GI tract, impaired GI motility, electrolyte imbalance, dehydration, on a low residue diet, taking medications that delay GI motility, constipation, pediatric patients with cystic fibrosis or Hirschsprung disease, and the elderly. To reduce the risk of delayed GI transit and obstruction, patients should maintain adequate hydration after the barium sulfate procedure. When administering VARIBAR PUDDING, consider the administration of laxatives. Aspiration Pneumonitis The use of VARIBAR PRODUCTS is contraindicated in patients with trachea-esophageal fistula. Oral administration of barium is associated with aspiration pneumonitis, especially in patients with a history of food aspiration or with compromised swallowing mechanism. Vomiting following oral administration of barium sulfate may lead to aspiration pneumonitis. In patients at risk for aspiration, begin the procedure with a small ingested volume of VARIBAR PRODUCTS. Monitor the patient closely for aspiration, discontinue administration of VARIBAR PRODUCTS if aspiration is suspected, and monitor for development of aspiration pneumonitis. Systemic Embolization Barium sulfate products may occasionally intravasate into the venous drainage of the GI tract and enter the circulation as a "barium embolus" leading to potentially fatal complications which include systemic and pulmonary embolism, disseminated intravascular coagulation, septicemia and prolonged severe hypotension. Although this complication is exceedingly uncommon after oral administration of a barium sulfate suspension, monitor patients for potential intravasation when administering barium sulfate. ADVERSE REACTIONS The most common adverse reactions are nausea, vomiting, diarrhea, and abdominal cramping. Serious adverse reactions and fatalities include aspiration pneumonitis, barium sulfate impaction, intestinal perforation with consequent peritonitis and granuloma formation, vasovagal and syncopal episodes. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please click here for full Prescribing Information for VARIBAR® THIN LIQUID (barium sulfate) oral suspension. Please click here for full Prescribing Information for VARIBAR® THIN HONEY (barium sulfate) oral suspension. Please click here for full Prescribing Information for VARIBAR® NECTAR (barium sulfate) oral suspension. Please click here for full Prescribing Information for VARIBAR® HONEY (barium sulfate) oral suspension. Please click here for full Prescribing Information for VARIBAR® PUDDING (barium sulfate) oral paste. VARIBAR is manufactured by E-Z-EM Canada Inc., for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc., Princeton, NJ 08540. VARIBAR is a registered trademark of E-Z-EM, Inc. For additional information about Bracco's products, and for full prescribing information, please visit . About Bracco Imaging Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. Discover Bracco at Bracco Diagnostics Inc. Media Relations (USA) Kimberly Gerweck Senior Compliance & Communications Manager [email protected] D: +1 609-524-2777 ______________________________ Hazelwood RJ, Armeson KE, Hill EG, et al. Identification of swallowing tasks from a modified barium swallow study that optimize the detection of physiological impairment. J Speech Lang Hear Res. 2017 Jul;60(7):1855-1863. Hind J, Divyak E, Zielinski J, et al. Comparison of standardized bariums with varying rheological parameters on swallowing kinematics in males. J Rehabil Res Dev. 2012;49(9):1399-1404. doi: 10.1682/jrrd.2011.09.0180. Robbins J, Nicosia M, Hind JA, et al. Defining physical properties of fluids for dysphagia evaluation and treatment. Perspectives on Swallowing and Swallowing Disorders (dysphagia). 2002 Jun;11(2):16-19. Martin-Harris, B., Humphries, K., Garand, K.L. The Modified Barium Swallow Impairment Profile (MBSImP™©) – Innovation, Dissemination and Implementation. Perspectives of the ASHA Special Interest Groups. 2017 Dec;2(4):129-138. SOURCE Bracco Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

10 Sep 2024

·www.prnewswire.com

ICP DAS-BMP Reveals Advanced Engineering TPUs at Medtec China 2024

HSINCHU, Sept. 9, 2024 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based medical TPU (thermoplastic polyurethane) manufacturer and supplier, is excited to announce its participation in Medtec China 2024. The 18th edition of this exhibition will be held from September 25-27, 2024, at the Shanghai World Expo Exhibition and Convention Center. Continue Reading ICP DAS-BMP Reveals Advanced Engineering TPUs at Medtec China 2024 At Medtec China 2024, ICP DAS-BMP will unveil its latest innovation, the Engineering Arothane™ TPU (EARP series). This medical-grade aromatic polyester-based rigid TPU stands out due to its excellent processability, high glass transition temperature (Tg) and exceptional light transmission properties. It is suitable for use as a rigid medical connector or as an auxiliary material in orthodontic treatment. Another highlight of ICP DAS-BMP's exhibit will be the Arothane™ ARP-W-G series. This aromatic polyether-based TPU is infused with 40-60% Tungsten as a radiopacifier. It boasts superior radiopacity compared to Barium Sulfate, which is critical for small-dimension or thin-walled medical devices. The ARP-W-G series is also known for its small pellet size, high fluidity, and excellent dispersion, making it a preferred choice for guidewire coating materials. In addition to these innovations, ICP DAS-BMP will also showcase Arothane™ ARP-B20 (20% Barium Sulfate) and Durathane™ ALC-B40 (40% Barium Sulfate). Both of these products have successfully passed the 90-day implantation test in accordance with the ISO 10993-6 standard. In response to market demand, ICP DAS-BMP is excited to announce the upcoming launch of its new ARP series soft materials with hardness levels below 70A. This series includes the ARP-60A, ARP-63A, and ARP-67A, providing customers with a broader range of options to meet various medical application needs. The ICP DAS-BMP team looks forward to welcoming trade show visitors from September 25th to 27th at booth 2B302. Attendees are invited to engage with the company's experts to explore the latest advancements in medical-grade TPU and discuss tailored solutions for their specific needs. About ICP DAS-BMP ICP DAS-BMP, a Taiwan-based TPU manufacturer and supplier certified with ISO 13485, operates specialized laboratories dedicated to quality management. Leveraging over three decades of industrial automation expertise from its parent company ICP DAS, ICP DAS-BMP employs smart factory practices to enhance product quality and expedite delivery times. The company is committed to providing responsive after-sales support and flexible solutions, even for small order quantities, ensuring customer satisfaction and fostering long-term partnerships. For more information, please visit: For TPU products and inquiries, contact: [email protected] SOURCE ICP DAS Co., Ltd.

100 Deals associated with Barium Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D02052	-	V08BA	DB11150

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Mouth Diseases	United States	Bracco Diagnostics, Inc.	07 Jul 2017
Pharyngeal Diseases	United States	Bracco Diagnostics, Inc.	07 Jul 2017
Duodenal Diseases	Japan	Fushimi Pharmaceutical Co., Ltd.	04 Mar 2002
Esophageal Diseases	Japan	Fushimi Pharmaceutical Co., Ltd.	04 Mar 2002
Stomach Diseases	Japan	Fushimi Pharmaceutical Co., Ltd.	04 Mar 2002
Gastrointestinal Diseases	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	20 Dec 1989
Contrast agents	Japan	Kaigen Pharma Co., Ltd.	31 Mar 1970

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis